Zusammenfassung
Hintergrund
Kaum eine Erkrankung in der Hämatologie entwickelt sich so dynamisch wie das multiple Myelom (MM) in den letzten Jahren. Dies betrifft sowohl therapeutische wie auch diagnostische Möglichkeiten.
Ziel
In diesem Übersichtsartikel werden die gegenwärtige Standarddiagnostik des MM dargestellt und ein Ausblick auf zukünftige Diagnostika aufgezeigt.
Ergebnisse und Schlussfolgerung
In absehbarer Zeit wird die Überprüfung einer persistierenden minimalen Resterkrankung nach Therapie sowie der Einsatz funktioneller Bildgebung Einzug in die Standarddiagnostik des MM halten. Die ersten positiven Studienergebnisse für zielgerichtete Therapien für genetisch determinierte Myelomsubgruppen – Venetoclax für t(11;14)-positive Patienten – legen zudem die Notwendigkeit einer Ausweitung der genetischen Diagnostik für MM-Patienten nahe.
Abstract
Background
Multiple myeloma (MM) is one of the most dynamically developing diseases in hematology in recent years. Ongoing progress is seen in treatment and diagnostic options are also improving tremendously.
Objective
In this review the state of the art of the diagnostics of MM is presented and an outlook on innovative technologies is given.
Results and conclusion
In the foreseeable future the detection of persisting minimal residual disease after treatment and the use of functional imaging will be incorporated into standard workflows for MM. The first positive study results for targeted treatment of genetically determined myeloma subgroups, the BCL2 inhibitor venetoclax for t(11;14) positive myeloma patients, additionally indicate the necessity for extending genetic diagnostic testing for MM patients.
Literatur
Cavo M, Terpos E, Nanni C et al (2017) Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 18:e206–e217
Chng WJ, Chung TH, Kumar S et al (2016) Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia 30:1071–1078
Dispenzieri A, Kyle R, Merlini G et al (2009) International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:215–224
Engelhardt M, Dold SM, Ihorst G et al (2016) Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica 101:1110–1119
Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420
Jimenez-Zepeda VH, Duggan P, Neri P et al (2016) Revised international staging system applied to real world multiple myeloma patients. Clin Lymphoma Myeloma Leuk 16:511–518
Kastritis E, Terpos E, Roussou M et al (2017) Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica 102:593–599
Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328–e346
Martinez-Lopez J, Lahuerta JJ, Pepin F et al (2014) Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123:3073–3079
Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33:2863–2869
Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548
Roshal M, Flores-Montero JA, Gao Q et al (2017) MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8‑color 2‑tube methods. Blood Adv 1:728–732
Sonneveld P, Avet-Loiseau H, Lonial S et al (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127:2955–2962
Tacchetti P, Pezzi A, Zamagni E et al (2017) Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents. Haematologica 102:e104–e107
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Kortüm, M. Bittrich und M. Schreder geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Kortüm, M., Bittrich, M. & Schreder, M. Moderne Diagnostik des multiplen Myeloms. Onkologe 24, 609–612 (2018). https://doi.org/10.1007/s00761-018-0389-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-018-0389-9